L. Blonde, E. Klein, Jenny Han
Jul 1, 2006
Citations
22
Influential Citations
430
Citations
Quality indicators
Journal
Diabetes
Abstract
Aim: Exenatide, an incretin mimetic for the adjunct treatment of type 2 diabetes (DM2), reduced A1C and weight in 30‐week placebo‐controlled trials. This analysis examined the effects of exenatide on glycaemic control and weight over an 82‐week period in patients with DM2 unable to achieve adequate glycaemic control with sulphonylurea (SU) and/or metformin (MET).